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Abstract. The in vitro activity of nine antimalarials was determined against 119 fresh clinical isolates of Plas- 
modium falciparum obtained from symptomatic indigenous patients in Yaounde, Cameroon, using the isotopic sem- 
imicrotest. Seventy-four parasites were resistant to chloroquine (mean 50% inhibitory concentration [IC5o] 337 a); 
45 were chloroquine-sensitive (mean ICso 35.6 nM). Twenty-five of 58 chloroquine-resistant parasites were resistant 
to monodesethylamodiaquine, the biologically active metabolite of amodiaquine. None of the chloroquine-sensitive 
isolates was resistant to monodesethylamodiaquine (IC50 17.3 nM). Pyronaridine, quinine, mefloquine, halofantrine, 
and artemether were highly active against the chloroquine-sensitive and the chloroquine-resistant isolates. Of the 43 
isolates tested, 25 were sensitive to both pyrimethamine and cycloguanil, the biologically active metabolite of pro- 
guanil. The in vitro responses of chloroquine and monodesethylamodiaquine, chloroquine and quinine, quinine and 
mefloquine, mefloquine and halofantrine, artemether and mefloquine or halofantrine, and pyrimethamine and cyclo- 
guanil were significantly correlated. The present study suggests that chloroquine resistance is highly prevalent in vitro 
in Yaounde and that the alternative drugs are generally highly active against the chloroquine-resistant parasites. 
Malaria is one of the most prevalent parasitic diseases in 
Cameroon, central Africa. Malaria transmission is seasonal 
in the northern half of the country, dominated by savanna, 
and continuous throughout the year in the southern tropical 
rain forest.' A large majority of malaria infections are due 
to Plasmodium falciparum. 
Chloroquine-resistant P. falciparum was first detected in 
expatriates in Limbe, a coastal town in southern Cameroon, 
and in African patients in Yaounde in 1985-1986.2*3 During 
this period, more than 65% of falciparum isolates from Lim- 
be were resistant in vitro to ch loroq~ine .~ .~  Brasseur and oth- 
ers6 found full sensitivity to chloroquine among the isolates 
obtained in other localities in southern Cameroon in 1985. 
Since then, several in vitro studies have demonstrated the 
spread of chloroquine resistance to other parts of the coun- 
try?. 7-12 The proportion of chloroquine-resistant isolates 
seems to have stabilized at 5040% in southern Came- 
roon.*'* l3 
Yaounde, the study site of the present study, is the capital 
city of Cameroon with an estimated population of 1,000,000. 
It is situated in the continuous malaria transmission zone in 
the southern highlands at an average altitude of 760 meters 
above sea level. The city is surrounded by a dense tropical 
rain forest. The equatorial climate is characterized by two 
rainy seasons (March-May, September-November) and two 
dry seasons (December-February, June-August). Both chil- 
dren and adults are affected by acute uncomplicated malaria, 
the children being symptomatic approximately two or three 
times more often than adults (Ringwald P, unpublished data). 
PrevioÚs epidemiologic studies of drug resistance have an- 
alyzed the response of Cameroonian isolates of P. falcipa- 
ruin to the standard antimalarials chloroquine, quinine, and 
mefloq~ine.~-~ Yaounde is one of the urban sites in which 
both in vitro tests and in vivo studies in symptomatic pa- 
tients have been conducted regularly by the Organisation de 
la Lutte contre les Endemies en Afrique Centrale 
(OCEAC).lO.'' The aims of the present study were 1) to de- 
termine thë in vitro response of fresh clinical isolates to stan- 
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dard antimalarials chloroquine, monodesethylamodiaquine 
(the biologically active metabolite of amodiaquine), quinine, 
pyrimethamine, and cycloguanil (the biologically active me- 
tabolite of proguanil), as well as to newer drugs (mefloquine, 
halofantrine, artemether, and pyronaridine) and 2) to evalu- 
ate whether there is a positive correlation between the in 
vitro responses to different antimalarials. The in vitro data 
were compared with the clinical efficacy of the drugs in 
recent clinical trials conducted in Yaounde. 
MATERIALS AND METHODS 
Parasites. One hundred nineteen fresh clinical isolates of 
P. falciparum were obtained before treatment from symp- 
tomatic, African adult and pediatric patients attending the 
Nlongkak dispensary in Yaounde between April 1994 and 
March 1995. The patients were questioned about drug intake 
and screened for self-medication by the urine test of Saker- 
solo mon^.^^ Due to cross-reactivity, the urine assay gives a 
positive result for chloroquine, quinine, mefloquine, pro- 
guanil, cycloguanil, and pyrimethamine. Giemsa-stained thin 
blood smears were examined for parasite identification, and 
parasite density was determined against 5,000 erythrocytes. 
Five to ten milliliters of venous blood were collected in a 
tube coated with EDTA (Terumo Europe N. V., Leuven, Bel- 
gium) after patients' informed consent was obtained. A 
smaller volume of blood was obtained from young children. 
Samples with a monoinfection due to P. falciparum and a 
parasite count > 0.2% from patients whose urine test result 
was negative were used in this study. All drug assays were 
performed within 5 hr after blood extraction. 
Drugs. Chloroquine Sulfate was provided by Specia (Par- 
is, France), monodesethylamodiaquine by Parke-Davis 
(Courbevoie, France), mefloquine hydrochloride by 
Hoffman-La Roche (Basel, Switzerland), and halofantrine 
hydrochloride by Smithmine & Beecham (Hertfordshire, 
United Kingdom). Pyronaridine tetraphosphate was provided 
by Professor c. Chen (Institute of Parasitic Diseases, Shang- 
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hai, China). Cycloguanil base was supplied by Imperial 
Chemical Industries (Hertfordshire, United Kingdom). Qui- 
nine hydrochloride and pyrimethamine base were obtained 
from the Sigma Chemical Company (St. Louis, MO). Arte- 
mether was obtained from Rhone-Poulenc-Rorer (Antony, 
France). Stock solutions of chloroquine, monodesethylamo- 
diaquine, and cycloguanil were prepared in sterile distilled 
water. Stock solutions of mefloquine, halofantrine, quinine, 
pyrimethamine, and artemether were prepared in methanol. 
Two-fold serial dilutions of the drugs were made in sterile 
distilled water. The final concentration of methanol did not 
exceed 0.1%, and the solvent alone did not affect the parasite 
growth. The final concentrations (in two-fold dilutions) 
ranged from 12.5 to 1,600 nM for chloroquine and quinine, 
1.25 to 160 nM for monodesethylamodiaquine and pyron- 
aridine, 2.5 to 400 nM for mefloquine, 0.25 to 32 nM for 
halofantrine, 0.5 to 64 nM for artemether, and 3.1 to 51,200 
nM (in four-fold dilutions) for cycloguanil and pyrimetham- 
ine. Each concentration was distributed in triplicate in 
24-well tissue culture plates. All isolates were tested against 
chloroquine. The isolates obtained from adult patients were 
tested against nine compounds. The isolates obtained from 
young children were tested against fewer antimalarials due 
to a smaller volume of blood extracted from these patients. 
In vitro drug sensitivity assay. The blood samples were 
washed three times in RPMI 1640 medium. The erythrocytes 
were resuspended in the complete RPMI 1640 medium, con- 
sisting of 10% human serum (obtained from European blood 
donors without previous history of malaria), 25 mM HEPES, 
and 25 mM NaHCO,, at a hematocrit of 1.5% and an initial 
parasitemia of 0.2-1.0%. A medium (RPMI 1640) with a 
low concentration of folic acid and p-aminobenzoic acid was 
used to assess the sensitivity to cycloguanil and pyrimetham- 
ine. If the blood sample had a parasitemia > 1.0%, fresh 
uninfected, type A+ erythrocytes were added to adjust the 
parasitemia to 0.6%. 
The isotopic semi-microtest described by Le Bras and De- 
loron was used in this study.15 Seven hundred microliters of 
the suspension of infected erythrocytes were distributed in 
each well of the 24-well tissue culture plates. The parasites 
were incubated at 37°C in 5% CO2 for 18 hr. To assess par- 
asite growth, 3H-hypoxanthine (specific activity 5 Cihmol,  
1 pCi/well; Amersham, Buckinghamshire, United Kingdom) 
was added. After an additional 24 hr of incubation, the plates 
were frozen to terminate the in vitro drug sensitivity assay. 
The plates were thawed, and the contents of each well were 
collected on glass-fiber filter papers, washed, and dried using 
a cell harvester. The filter disks were transferred into scin- 
tillation tubes, and 2 ml of scintillation cocktail (Organic 
Counting Scintillant@; Amersham) were added. The incor- 
poration of ,H-hypoxanthine was quantitated using a liquid 
scintillation counter (Wallac 1410; Pharmacia, Uppsala, 
Sweden). 
The 50% inhibitory concentration (IC&) values, defined 
as the drug Concentration corresponding to 50% of the up- 
take of ,H-hypoxanthine measured in the drug-free control 
wells, were determined by linear regression analysis of log- 
arithm of concentrations plotted against the logit of growth 
inhibition. The threshold IC,, values for in vitro resistance 
to chloroquine, monodesethylamodiaquine, quinine, meflo- 
quine, halofantrine, cycloguanil, and pyrimethamine were 
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estimated to be > 100 nM, > 60 nM, > 600 nM, > 30 nM, 
> 6 nM, > 50 nM, and > 100 nM, respectively.’”’* The 
resistance levels of artemether and pyronaridine are still un- 
defined. Data were expressed as geometric mean ICso values 
and the 95% confidence intervals. The mean IC,, values of 
various drugs were compared between the chloroquine-sen- 
sitive and the chloroquine-resistant isolates using the Stu- 
dent’s t-test. Correlation of the logarithmic values of IC,, for 
different drugs was calculated by a linear regression analy- 
sis. Data were analyzed with the Statview software (Abacus 
Concepts, Inc., Calabasas, CA). Several assays were not in- 
terpretable due to bacterial contamination or technical error 
in the preparation of test plates and were excluded from data 
analysis. 
RESULTS 
Seventy-four (62%) of 119 fresh clinical isolates of P. 
falciparum were resistant to chloroquine (geometric mean 
IC,, 337 nM) (Table 1). The mean IC,, value of 45 chloro- 
quine-sensitive isolates was 35.6 nM. Ninety isolates were 
tested for their sensitivity to monodesethylamodiaquine. 
Twenty-five (28%) isolates were resistant in vitro to mono- 
desethylamodiaquine; all of them were also resistant to chlo- 
roquine. Of the 65 isolates sensitive to monodesethylamo- 
diaquine, 33 (5 1 %) were chloroquine-resistant. The mean 
IC,, values for pyronaridine were 5.15 nM and 4.92 nM 
against the chloroquine-sensitive isolates and the chloro- 
quine-resistant parasites (a total of 103 isolates tested), re- 
spectively. Four of 100 isolates were resistant in vitro to 
quinine (IC,, values 606 nM, 61 1 nM, 756 nM, and 1,047 
nM): two isolates had IC,, values that were very close to the 
threshold value (IC,, 600 nM). The quinine-resistant isolates 
were resistant to chloroquine. Ninety-two isolates were test- 
ed for sensitivity to mefloquine and halofantrine. Two par- 
asites were resistant in vitro to mefloquine and halofantrine 
(IC,, 31 nM and 6.6 nM, respectively) or to mefloquine 
alone (IC,, 36 nM). In both isolates, the IC,, values slightly 
exceeded the cutoff points (30 nM for mefloquine, 6 nM for 
halofantrine). Artemether was highly active (ICso 5 11.0 
nM) against all 85 isolates tested. Of the 43 isolates tested, 
25 (58%) were sensitive to both cycloguanil (mean IC,, 8.79 
nM) and pyrimethamine (mean IC,, 16.3 nM) (Table 2). 
Fourteen and 16 isolates were highly resistant (cycloguanil 
IC,, > 500 nM, pyrimethamine ICso > 2,000 nM) to cyclo- 
guanil (ICso 1,030 nM) and pyrimethamine (ICso 7,710 nM), 
respectively. 
The IC,, values of chloroquine-resistant isolates for mon- 
odesethylamodiaquine (53.2 nM) and quinine (239 nM) were 
significantly higher (P < 0.05) than the IC,, values of chlo- 
roquine-sensitive isolates (17.3 nM and 108 nM, respective- 
ly). The chloroquine-resistant isolates had lower mean IC,, 
values for artemether (1.61 nM) in comparison with the 
chloroquine-sensitive isolates (2.37 nM). The activity of me- 
floquine, halofantrine, and pyronaridine did not differ (P > 
0.05) between the chloroquine-sensitive isolates and the 
chloroquine-resistant isolates. The in vitro responses of chlo- 
roquine and monodesethylamodiaquine (r = 0.8 17), chloro- 
quine and quinine (r = 0.557), quinine and mefloquine (r = 
0.505), mefloquine and halofantrine (r = 0.693), artemether 
and mefloquine (r = 0.627) or halofantrine (r = 0.609), and 
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TABLE 1 
In vitro drug sensitivity patterns of Plasmodium falciparum parasites isolated in Yaounde, Cameroon in 1994-1995 
Drug susceptibility (nM)* 
Chloroquine-resistant (n = 74) Chloroquine-sensitive (n = 45) 
95% confidence limits ICJO 95% confidence limits D W  ICJO 
Chloroquine 35.6 30.6-41.5 337 305-372 
Monodesethylamodiaquine 17.3 14.0-21 -3 53.2 46.2-61.1 
4.14-5.86 Pyronaridine 5.15 4.18-6.35 4.92 
Quinine 108 87.1-134 239 199-287 
Mefloquine 7.38 5.79-9.40 8.47 
Halofantrine 1.32 1.04-1.66 1.22 
6.78-10.6 
1.04-1.44 
Artemether 2.37 1.91-2.94 1.61 1.30-2.00 
*Values are the geometric mean 50% inhibitory concentration (IC,& 
cycloguanil and pyrimethamine (r = 0.975) were signifi- 
cantly correlated (Table 3). 
DISCUSSION 
The in vitro activity of a wide range of reference anti- 
malarials as well as newer antimalarial agents was deter- 
mined against fresh isolates of P. falciparum obtained in the 
urban setting in Yaounde, Cameroon. In the previous in vitro 
studies conducted in Yaounde, it had been shown that about 
SO-60% of P. falciparum were resistant to chloroquine, both 
in vivo and in vitr0.I' A similar proportion of parasites were 
resistant in vitro to chloroquine in the present study. 
Because of the cross-resistance between chloroquine and 
amodiaquine in highly chloroquine-resistant areas in Asia 
and the possibility of hematologic and hepatic toxicity of 
amodiaquine when it is used for chemoprophylaxis, the 
World Health Organization (WHO) no longer recommends 
the use of amodiaquine for malaria treatment or prophylax- 
is.19 However, recent clinical studies conducted in Africa 
demonstrate the high efficacy of amodiaquine and lack of 
serious toxic effects.20-22 The in vitro data also suggest the 
high activity of amodiaquine against most chloroquine-resis- 
tant isolates and tend to support the clinical efficacy of amo- 
diaquine in central and West Africa.4. Cross-resistance 
between chloroquine and amodiaquine suggested by these in 
vitro studies as well as by the present study has so far not 
been observed in the clinical practice in Yaounde. 
The in vitro studies of Brasseur and others5.I3 have sug- 
gested the presence of a considerable number of quinine- 
resistant isolates (up to 25%) in southern Cameroon. In re- 
cent clinical studies involving a total of 113 patients in 
Yaounde, 10 cases of therapeutic failure with quinine (oral 
or parenteral administration of 25 mg of basekglday for 3- 
5 days) have been reported with a recrudescence of parasit- 
emia on day 14J4"7 At least three of 10 treatment failures 
were ascribed to poor compliance. The other cases of treat- 
ment failure were probably not true cases of quinine resis- 
tance since the duration of quinine therapy was only three 
days, instead of the standard seven days, and some of these 
patients responded to a second quinine treatment given over 
3-5 days. The clinical efficacy of quinine is supported by 
the in vitro data of the present study and those of other 
studies that suggest high activity of quinine against a large 
majority of Cameroonian isolates in Yaounde.li.23*28 The 
wide discrepancy between the in vitro predictions of Bras- 
seur and others and the high clinical efficacy of quinine is 
probably due to the low threshold level for in vitro resistance 
to quinine set by these investigators (IC5, > 300 nM). 
Sulfadoxine-pyrimethamine (for treatment) and pyrime- 
thamine alone (for prophylaxis in pregnant women) have 
been widely used in Cameroon since the late 1980s. Cam- 
eroon has recorded the highest volume of consumption of 
these two drugs in francophone Africa. A clinical trial con- 
ducted in the late 1980s in Yaounde showed the full efficacy 
of sulfadoxine-pyrimethamine26 The first case of resistance 
to this drug in Cameroon was reported in 1987 in a non- 
immune traveler on chemoprophylaxis with sulfadoxine-pyr- 
imethamine, who failed to respond to the same drug com- 
bination given at the therapeutic d0se.2~ Our in vitro data 
suggest higher activity of pyrimethamine against 58% of 
Cameroonian isolates. The presence of highly pyrimetham- 
ine-resistant isolates (37% of the isolates tested) seems to 
reflect the drug pressure exerted in the country for almost a 
decade. More recent clinical evaluation of the efficacy of 
TABLE 2
In vitro susceptibility of Cameroonian isolates of Plasmodium falciparum to pyrimethamine and cycloguanil 
~~ 
In vitro response (nM)* 
Intermediatet Resistantt Susceptiblet 
95% confidence 95% confidence 
Drug IC,, limits G o  Range IC,, limits 
7,710 6,110-9,750 
778-1,360 
Pyrimethamine 16.3 11.8-22.7 409 179-936 
(n = 25) (n = 2) (n = 16) 
(n = 25) (n = 4) (n = 14) 
Cycloguanil 8.79 6.73-1 1.5 144 56.2-366 1,030 
* Values are the geometric mean 50% inhibitory concentration (IC,& 
t Based on the previous study on African isolares 17 in vitro response was defined as susceptible (IC, < 100 nM for pyrimethamine. < 50 nM for cycloguanil), intermediate (ICTo 100- 
2.000 nM for pyrimethamine, 50-500 nM for cycloguanil), and resistant (IC," > 2,000 nM for pyrimethamine. > 500 nM for cycloguanil). 
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TABLE 3 
Correlation of in vitro responses of antimalarial drugs against Cam- 
eroonian isolates of Plasmodium fakiparum* 
Correlation Prob- 
Drug pairs coefficient ability 
Chloroquine 
Chloroquine 
Chloroquine 
Chloroquine 
Chloroquine 
Chloroquine 
Quinine 
Quinine 
Mefloquine 
Mefloquine 
Halofantrine 
Cycloguanil 
Monodesethylamodiaquine 
Pyronaridine 
Quinine 
Mefloquine 
Halofantrine 
Artemether 
Mefloquine 
Halofantrine 
Halofantrine 
Artemether 
Artemether 
Pyrimethamine 
0.817 
0.047 
0.557 
0.264 
0.064 
-0.083 
0.505 
0.373 
0.693 
0.627 
0.609 
0.975 
<0.01 
NS 
<0.01 
0.02 
NS 
NS 
<0.01 
<0.01 
<0.01 
co.01 
<0.01 
<0.01 
The correlation coefficient (r) was calculated by linear rcgrcssion analysis of logarithmic 
50% inhibitory concentration values. Probability refers to the significance level of the test 
(P C 0.05). NS = nonsignificant. 
sulfadoxine-pyrimethamine and regular epidemiologic mon- 
itoring are needed to confirm the in vitro findings. 
Proguanil, in combination with chloroquine, is one of the 
recommended chemoprophylactic regimens for indigenous 
pregnant women and nonimmune travelers and residents. 
Chloroquine-proguanil is well-tolerated and generally effec- 
tive for long-term use. Clinical trials in Yaounde have shown 
that most nonimmune residents on chloroquine-proguanil 
were pr0tected.~~*3~ As with pyrimethamine, the in vivo re- 
sponse to chloroquine-proguanil should be monitored peri- 
odically to ensure its efficacy. The high correlation of the in 
vitro response to pyrimethamine and cycloguanil was ex- 
pected since both drugs act on the same molecular target, 
dihydrofolate reductase-thymidylate synthase. 
Of the new antimalarials evaluated in our study, pyron- 
aridine, artemether, mefloquine, and halofantrine displayed a 
high in vitro activity. Pyronaridine and artemether have been 
shown to be active in vitro against African isolates in pre- 
vious studies.32+ 33 They have undergone clinical evaluation 
in Yaounde, and both drugs were shown to be highly effec- 
tive (Louis F, unpublished The high efficacy of hal- 
ofantrine to treat malaria in symptomatic African adult pa- 
tients has been demonstrated in a clinical trial conducted in 
Yaounde in 1990-1991.35 Our own experience in success- 
fully treating recrudescent adult and pediatric cases with hal- 
ofantrine after correct chloroquine therapy lends further sup- 
port to its high clinical efficacy. Mefloquine is not available 
in Cameroon, except in a form of the triple combination, 
mefloquine-sulfadoxine-pyrimethamine, that has not been 
widely used in a community or national level. The efficacy 
of this combination and that of mefloquine alone (15 mgkg 
in a single dose) has been demonstrated in Yaounde (Ring- 
Wald P, unpublished data).36 Based on slow parasite clearance 
in healthy asymptomatic schoolchildren, Brasseur and oth- 
ers3’ have concluded that RII-RIII levels of mefloquine re- 
sistance exist in northern Cameroon. However, according to 
the inclusion criteria of the vivo test defined by the WHO, 
asymptomatic parasite carriers are not suitable subjects for 
clinical trials that aim to evaluate clinical efficacy. 
Amodiaquine is becoming one of the first-line drug in 
Yaounde and in some other parts of Cameroon. Regular 
monitoring of the clinical efficacy of amodiaquine and its 
correct therapeutic use are therefore needed to ensure its 
maximal utility. Because of the limited availability of the 
newer drugs in the country, the positive in vitro correlation 
between mefloquine and halofantrine does not have any clin- 
ical repercussion at present. The in vitro and in vivo sur- 
veillance of pyrimethamine and cycloguanil is necessary as 
sulfadoxine-pyrimethamine becomes widely used for the 
treatment of chloroquine-resistant cases. The high in vitro 
activity of the newer antimalarial drugs assessed in the pres- 
ent study is supported by recent clinical trials in the same 
urban ~ e t t i n g . ~ ~ ” ~  In vitro drug assays, in conjunction with 
clinical studies, are valuable tools in monitoring the status 
of the rapidly changing epidemiology of drug resistance and 
in guiding the national antimalarial drug policy. 
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